natgillin/translations-raw huggingface dataset:
Hos patienter, hvor hastigheden af uratdannelsen er kraftigt forøget (f.eks. malign sygdom og dens behandling, Lesch-Nyhan-syndrom), kan den absolutte koncentration af xanthin i urinen i sjældne tilfælde stige så meget, at der sker aflejring i urinvejene. 
In patients in whom the rate of urate formation is greatly increased (e.g. malignant disease and its treatment, Lesch-Nyhan syndrome) the absolute concentration of xanthine in urine could, in rare cases, rise sufficiently to allow deposition in the urinary tract.
I FLORENCE-studiet viste febuxostat en overlegen kontrol af serumurinsyreniveauet sammenlignet med allopurinol hos patienter, som var planlagt til at skulle have sidstnævnte lægemiddel. 
In the FLORENCE study febuxostat demonstrated a superior control of serum uric acid level compared to allopurinol in patients scheduled to receive the latter drug.
Hepatitis, gulsot*, leverskader* 
Hepatitis, jaundice*, liver injury*
Der sås en numerisk højere forekomst af investigator-indberettede kardiovaskulære APTC-hændelser (definerede endepunkter fra Anti-Platelet Trialists' Collaboration (APTC), der inkluderer kardiovaskulær død, ikke-letalt myokardieinfarkt, ikke-letal apopleksi) i den samlede febuxostatgruppe sammenlignet med allopurinolgruppen i APEX- og FACT-studierne (1,3 versus 0,3 hændelser pr. 100 patientår), men ikke i CONFIRMS-studiet (se pkt. 
A numerical greater incidence of investigator-reported cardiovascular APTC events (defined endpoints from the Anti-Platelet Trialists' Collaboration (APTC) including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) was observed in the febuxostat total group compared to the allopurinol group in the APEX and FACT studies (1.3 vs. 0.3 events per 100 Patient Years (PYs)), but not in the CONFIRMS study (see section 5.1 for detailed characteristics of the studies).
Farmakoterapeutisk klassifikation: Midler mod arthritis urica, midler der hæmmer urinsyreproduktionen, ATC-kode: M04AA03. 
Pharmacotherapeutic group: Antigout preparations, preparations inhibiting uric acid production; ATC code: M04AA03.
Febuxostat Krka virker tilstrækkeligt hurtigt til, at serumurinsyren kan testes igen efter to uger. 
Febuxostat Krka works sufficiently quickly to allow retesting of the serum uric acid after 2 weeks.
Sikkerhed og virkning er ikke fuldstændig klarlagt hos patienter med svært nedsat nyrefunktion (kreatininclearance < 30 ml/min, se pkt. 
The efficacy and safety have not been fully evaluated in patients with severe renal impairment (creatinine clearance <30 mL/min, see section 5.2).
CONFIRMS-studiet: CONFIRMS-studiet var et randomiseret, kontrolleret, 26-ugers, fase 3-studie til evaluering af sikkerhed og virkning af febuxostat 40 mg og 80 mg ved sammenligning med allopurinol 300 mg eller 200 mg hos patienter med arthritis urica og hyperurikæmi. 
CONFIRMS Study: The CONFIRMS study was a Phase 3, randomized, controlled, 26-week study to evaluate the safety and efficacy of febuxostat 40 mg and 80 mg, in comparison with allopurinol 300 mg or 200 mg, in patients with gout and hyperuricaemia.
Atrieflimren, palpitationer, unormalt EKG Sjældne 
Atrial fibrillation, palpitations, ECG abnormal Rare
Forekomsten af investigator-indberettede kardiovaskulære APTC-hændelser i de kombinerede fase 3-studier (APEX, FACT og CONFIRMS), var 0,7 versus 0,6 hændelser pr. 100 patientår. 
The incidence of investigator-reported cardiovascular APTC events in the combined Phase 3 studies (APEX, FACT and CONFIRMS studies) was 0.7 vs. 0.6 events per 100 PYs.
14 filmovertrukne tabletter 28 filmovertrukne tabletter 56 filmovertrukne tabletter 84 filmovertrukne tabletter 
14 film-coated tablets 28 film-coated tablets 56 film-coated tablets 84 film-coated tablets
Sjældne Sløret syn 
Rare Blurred vision
Febuxostat Krka 120 mg tabletter anvendes også til at behandle og forebygge forhøjet indhold af urinsyre i blodet, som kan forekomme, når du begynder at få kemoterapi mod blodkræft. 
Febuxostat Krka 120 mg tablets are also used to treat and prevent high blood levels of uric acid that may occur when you start to receive chemotherapy for blood cancers.
FOCUS studiet (TMX-01-005) var et 5-årigt, åbent, forlænget, fase 2-multicenterstudie til evaluering af sikkerheden hos patienter, som havde gennemført studie TMX-00-004 med 4 ugers febuxostatbehandling i et dobbeltblindt design. 
FOCUS Study (TMX-01-005) was a 5 years Phase 2, open-label, multicenter, safety extension study for patients who had completed the febuxostat 4 weeks of double blind dosing in study TMX-00-004.
Serumuratniveauerne blev opretholdt over tid (dvs. 91 % og 93 % af de patienter, der fik initial behandling med henholdsvis febuxostat 80 mg og 120 mg, havde serumurat < 6 mg/dl ved måned 36). 
Serum urate levels were maintained over time (i.e. 91% and 93% of patients on initial treatment with febuxostat 80 mg and 120 mg, respectively, had sUA <6 mg/dL at Month 36).
Febuxostat kan derfor tages uden hensyntagen til fødeindtagelse. 
Thus, febuxostat may be taken without regard to food.
Forebyggelse og behandling af høje urinsyreniveauer hos patienter i kemoterapi mod kræft Febuxostat Krka fås som en 120 mg tablet. 
Prevention and treatment of high uric acid levels in patients undergoing cancer chemotherapy Febuxostat Krka is available as a 120 mg tablet.
14 filmovertrukne tabletter: EU/1/18/1347/001 28 filmovertrukne tabletter: EU/1/18/1347/002 56 filmovertrukne tabletter: EU/1/18/1347/003 84 filmovertrukne tabletter: EU/1/18/1347/004 
14 film-coated tablets: EU/1/18/1347/001 28 film-coated tablets: EU/1/18/1347/002 56 film-coated tablets: EU/1/18/1347/003 84 film-coated tablets: EU/1/18/1347/004
Reduktionen i serumurinsyreniveauerne til < 6 mg/dl (357 μmol/l) blev observeret ved uge 2-besøget og blev vedligeholdt gennem hele behandlingen. 
Reduction in serum uric acid level to <6.0 mg/dL (357 μmol/L) was noted by the Week 2 visit and was maintained throughout treatment.
14 filmovertrukne tabletter: EU/1/18/1347/005 28 filmovertrukne tabletter: EU/1/18/1347/006 56 filmovertrukne tabletter: EU/1/18/1347/007 84 filmovertrukne tabletter: EU/1/18/1347/008 
14 film-coated tablets: EU/1/18/1347/005 28 film-coated tablets: EU/1/18/1347/006 56 film-coated tablets: EU/1/18/1347/007 84 film-coated tablets: EU/1/18/1347/008
Hjælpestof, som behandleren skal være opmærksom på - lactose: 73 mg 
Excipient(s) with known effect - lactose: 73 mg
Patienter, som fik målt 3 konsekutive serumurinsyreniveauer > 6,0 mg/dl, udgik af studiet. 
Patients who had 3 consecutive sUA levels >6.0 mg/dL were withdrawn.
Der er rapporteret døsighed, svimmelhed, paræstesi og sløret syn i forbindelse med anvendelse af febuxostat. 
Somnolence, dizziness, paraesthesia and blurred vision have been reported with the use of febuxostat.
I det pivotale studie af tumorlysesyndrom blev der administreret 120 mg dagligt til patienter i flere forskellige kemoterapiregimer, herunder monoklonale antistoffer. 
In the Tumor Lysis Syndrome pivotal trial febuxostat 120 mg daily was administered to patients undergoing several chemotherapy regimens, including monoclonal antibodies.
Febuxostat Krka leveres i æsker med 14, 28, 56 eller 84 filmovertrukne tabletter i blisterpakninger. 
Febuxostat Krka is available in boxes containing 14, 28, 56 or 84 film-coated tablets in blisters.
Det primære effektmål i APEX- og FACT-studierne var den andel af patienterne, hvis sidste tre månedlige serumurinsyreniveauer var < 6,0 mg/dl (357 μmol/l). 
The primary efficacy endpoint in the APEX and FACT studies was the proportion of patients whose last 3 monthly serum uric acid levels were < 6.0 mg/dL (357 μmol/L).
Febuxostat metaboliseres i stort omfang ved konjugering via uridindiphosphat-glukuronosyltransferase (UDPGT)-enzymsystemet og oxidation via cytochrom P450 (CYP) -systemet. 
Febuxostat is extensively metabolized by conjugation via uridine diphosphate glucuronosyltransferase (UDPGT) enzyme system and oxidation via the cytochrome P450 (CYP) system.
Hvis serumurinsyre er > 357 μmol/l (6 mg/dl) efter 2-4 uger, bør det overvejes at give Febuxostat Krka 120 mg én gang dagligt. 
If serum uric acid is > 6 mg/dL (357 μmol/L) after 2-4 weeks, Febuxostat Krka 120 mg once daily may be considered.
Tabel 2 Andel patienter med serumurinsyreniveauer < 6 mg/dl (357 μmol/l) Sidste tre månedlige besøg 
Table 2 Proportion of Patients with Serum Uric Acid Levels <6.0 mg/dL (357 μmol/L) Last Three Monthly Visits
Vær opmærksom på, at du kan blive svimmel eller søvnig, få sløret syn eller opleve en følelsesløs eller prikkende fornemmelse under behandlingen med dette lægemiddel. 
Be aware that you may experience dizziness, sleepiness, blurred vision and numbness or tingling sensation during treatment with this medicine and should not drive or operate machines if affected.
Hjælpestof, som behandleren skal være opmærksom på - lactose: 109 mg 
Excipient(s) with known effect - lactose: 109 mg
Hos patienter, hvis urinsyreniveau er meget højt (f.eks. hvis man er i kemobehandling), kan behandling med urinsyresænkende medicin medføre, at der ophobes xanthin i urinvejene, evt. med dannelse af nyresten, selvom dette ikke er blevet observeret hos patienter, der behandles med febuxostat mod tumorlysesyndrom. 
In patients with very high urate levels (e.g. those undergoing cancer chemotherapy), treatment with uric acid-lowering medicines could lead to the build-up of xanthine in the urinary tract, with possible stones, even though this has not been observed in patients being treated with febuxostat for Tumor Lysis Syndrome.
Febuxostat Krka indeholder - Aktivt stof: febuxostat. 
What Febuxostat Krka contains - The active substance is febuxostat.
Efter enkelte eller gentagne orale doser på 80 og 120 mg én gang dagligt er Cmax henholdsvis cirka 2,8-3,2 μg/mL og 5,0-5,3 μg/mL. 
After single or multiple oral 80 and 120 mg once daily doses, Cmax is approximately 2.8-3.2 μg/mL, and 5.0-5.3 μg/mL, respectively.
APEX-studiet: APEX-studiet (Allopurinol and Placebo-Controlled Efficacy Study of Febuxostat) var et fase 3, randomiseret, dobbeltblindet, multicenterstudie over 28 uger. 
APEX Study: The Allopurinol and Placebo-Controlled Efficacy Study of Febuxostat (APEX) was a Phase 3, randomized, double-blind, multicenter, 28-week study.
Febuxostat har vist sig at inhibere både de oxiderede og reducerede former af XO kraftigt. 
Febuxostat has been shown to potently inhibit both the oxidized and reduced forms of XO. At therapeutic
Behandlingen med febuxostat bør ikke påbegyndes, før et akut anfald af arthritis urica har fortaget sig fuldstændig. 
Febuxostat treatment should not be started until an acute attack of gout has completely subsided.
Diabetes mellitus, hyperlipidæmi, nedsat appetit, vægtstigning 
Diabetes mellitus, hyperlipidemia, decrease appetite, weight increase Rare
Det skal du vide, før du begynder at tage Febuxostat Krka 
What you need to know before you take Febuxostat Krka
I et studie med raske forsøgspersoner resulterede 120 mg febuxostat en gang dagligt i en gennemsnitlig stigning på 22 % i AUC for desipramin, et CYP2D6-substrat, hvilket indikerer, at febuxostat har en potentiel, svag hæmmende virkning på CYP2D6-enzymet in vivo. 
In a study in healthy subjects, 120 mg febuxostat QD resulted in a mean 22% increase in AUC of desipramine, a CYP2D6 substrate indicating a potential weak inhibitory effect of febuxostat on the CYP2D6 enzyme in vivo.
Lactosemonohydrat Cellulose, mikrokrystallinsk Hydroxypropylcellulose Croscarmellosenatrium Silica, kolloid 
Lactose monohydrate Cellulose, microcrystalline Hydroxypropylcellulose Croscarmellose sodium Silica, colloidal hydrated Magnesium stearate
I tilfælde af en utilsigtet overdosering skal du spørge din læge om, hvad du skal gøre, eller du skal henvende dig på den nærmeste skadestue. 
If you take more Febuxostat Krka than you should In the event of an accidental overdose ask your doctor what to do, or contact your nearest accident and emergency department.
Hold op med at tage medicinen, hvis du får allergiske reaktioner på Febuxostat Krka (se også punkt 4). 
Should you experience allergic reactions to Febuxostat Krka, stop taking this medicine (see also section 4).
Febuxostat Krka er indiceret til forebyggelse og behandling af hyperurikæmi hos voksne patienter i behandling med kemoterapi for hæmatologiske maligniteter med en middel til høj risiko for tumorlysesyndrom. 
Febuxostat Krka is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).
Tabel 1: Bivirkninger i kombinerede langvarige fase 3- forlængelsesstudier og efter markedsføringen Blod og lymfesystem 
Table 1: Adverse reactions in combined phase 3, long-term extension studies and post-marketing experience
Febuxostat viste en overlegen og hurtigere evne til at sænke uratniveauet sammenlignet med allopurinol. 
Febuxostat showed a superior and faster urate lowering activity compared to allopurinol.
- Øvrige indholdsstoffer: lactosemonohydrat, mikrokrystallinsk cellulose, hydroxypropylcellulose, croscarmellosenatrium, kolloid silica og magnesiumstearat i tabletkernen og poly(vinylalkhol), macrogol 3350, titandioxid (E171), talcum, gul jernoxid (E172) - kun for 120 mg filmovertrukne tabletter og rød jernoxid (E172) - kun for 80 mg filmovertrukne tabletter i filmovertrækket. 
hydroxypropylcellulose, croscarmellose sodium, colloidal hydrated silica and magnesium stearate in the tablet core and poly(vinyl alcohol), macrogol 3350, titanium dioxide (E171), talc, yellow iron oxide (E172) - only for 120 mg film-coated tablets and red iron oxide (E172) - only for 80 mg film-coated tablets in the film coating.
Foruden renal udskillelse blev cirka 45 % af dosis genfundet i fæces som uændret febuxostat (12 %), det aktive stofs acyl-glukuronid (1 %), dets kendte oxidative metabolitter og deres konjugater (25 %) samt andre ukendte metabolitter (7 %). 
In addition to the urinary excretion, approximately 45% of the dose was recovered in the faeces as the unchanged febuxostat (12%), the acyl glucuronide of the active substance (1%), its known oxidative metabolites and their conjugates (25%), and other unknown metabolites (7%).
Det anbefales at give profylaktisk behandling mod anfald med et NSAID eller colchicin i mindst seks måneder i starten af behandlingen med febuxostat (se pkt. 
At treatment initiation with febuxostat flare prophylaxis for at least 6 months with an NSAID or colchicine is recommended (see section 4.2).
Febuxostats gennemsnitlige totale AUC steg cirka 1,8 gange fra 7,5 μg × time/ml hos gruppen med normal nyrefunktion til 13,2 μg × time/ml hos gruppen med svært nedsat nyrefunktion. 
The mean total AUC of febuxostat increased by approximately 1.8-fold from 7.5 μg⋅h/mL in the normal renal function group to 13.2 μg.h/mL in the severe renal dysfunction group.
Hvis du holder op med at tage Febuxostat Krka 
If you stop taking Febuxostat Krka
Derfor forventes samtidig administration af febuxostat og andre CYP2D6-substrater ikke at kræve dosisjustering af disse stoffer. 
Thus, coadministration of febuxostat with other CYP2D6 substrates is not expected to require any dose adjustment for those compounds.
Febuxostat er påvist at være en svag CYP2D6-hæmmer in vitro. 
Febuxostat was shown to be a weak inhibitor of CYP2D6 in vitro.
Hypertension, rødmen, hedeture, hæmoragi (se afsnittet Tumorlysesyndrom) 
Hypertension, flushing, hot flush, haemorrhage (see section Tumor Lysis Syndrome)
Febuxostats metabolisme er afhængig af UDP-glukuronosyltransferaser (UGT-enzymer). 
Febuxostat metabolism depends on Uridine Glucuronosyl Transferase (UGT) enzymes.
Ved terapeutiske koncentrationer hæmmer febuxostat ikke andre enzymer, der medvirker i purin- eller pyrimidinmetabolismen, dvs. guanin-deaminase, hypoxanthinguanin-phosphoribosyltransferase, orotat-phosphoribosyltransferase, orotidinmonophosphatdecarboxylase eller purinnukleosid-phosphorylase. 
concentrations febuxostat does not inhibit other enzymes involved in purine or pyrimidine metabolism, namely, guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotate phosphoribosyltransferase, orotidine monophosphate decarboxylase or purine nucleoside phosphorylase.
(angivet i punkt 6). 
(see also section 4.8).
Efter en oral dosis på 80 mg 
Following an 80 mg oral dose of
Hver filmovertrukket tablet indeholder 80 mg febuxostat. 
Each film-coated tablet contains 80 mg febuxostat.
Udbruddene tog til efter den 8 ugers profylaktiske periode, hvorefter de aftog gradvist med tiden (henholdsvis 64 % og 70 % af deltagerne blev behandlet for udbrud af arthritis urica i perioden uge 8-52). 
After the 8-week prophylaxis period, the incidences of flares increased and gradually decreased over time (64% and 70% of subjects received treatment for gout flares from Week 8-52).
C-mærket febuxostat blev cirka 49 % af dosis genfundet i urinen som uændret febuxostat (3 %), det aktive stofs acylglukuronid (30 %), dets kendte oxidative metabolitter og deres konjugater (13 %) og andre ukendte metabolitter (3 %). 
labeled febuxostat, approximately 49% of the dose was recovered in the urine as unchanged febuxostat (3%), the acyl glucuronide of the active substance (30%), its known oxidative metabolites and their conjugates (13%), and other unknown metabolites (3%).
Febuxostat Krka er indiceret til voksne. 
Febuxostat Krka is indicated in adults.
Lyserøde, ovale, bikonvekse, filmovertrukne tabletter med delekærv på den ene side. 
Off pink, oval, biconvex, film-coated tablets scored on one side.
Ikke almindelige Dyspnø, bronkitis, øvre luftvejsinfektion, hoste 
Dyspnoea, bronchitis, upper respiratory tract infection, cough
Abdominalsmerter, abdominal distension, gastroøsofageal reflukssygdom, opkastning, mundtørhed, dyspepsi, obstipation, hyppig afføring, flatulens, gastrointestinale gener Sjældne 
Abdominal pain, abdominal distension, gastrooesophageal reflux disease, vomiting, dry mouth, dyspepsia, constipation, frequent stools, flatulence, gastrointestinal discomfort Rare
Febuxostat Krka anvendes til voksne. 
Febuxostat Krka is for adults.
Tumorlysesyndrom: 
Tumor Lysis Syndrome:
Andelen af patienter med serumurat < 6 mg/dl (357 μmol/l) ved det sidste besøg var henholdsvis 45 % for febuxostat 40 mg, 67 % for febuxostat 80 mg og 42 % for allopurinol 300/200 mg. 
The proportion of patients with serum urate levels of < 6.0 mg/dL (357 μmol/L) at the final visit, was 45% for 40 mg febuxostat, 67% for febuxostat 80 mg and 42% for allopurinol 300/200 mg, respectively.
Hjerte: Ikke almindelig: Venstresidigt grenblok, sinustakykardi 
Cardiac disorders: Uncommon: Left bundle branch block, sinus tachycardia
Hver filmovertrukket tablet indeholder 120 mg febuxostat. 
Each film-coated tablet contains 120 mg febuxostat.
Febuxostat Krka 120 mg filmovertrukne tabletter (tabletter) er brungule, ovale, let bikonvekse, kapselformede filmovertrukne tabletter med delekærv på begge sider. 
Febuxostat Krka 120 mg film-coated tablets (tablets) are brownish yellow, slightly biconvex, capsule shaped film-coated tablets scored on both sides.
Febuxostat Krka bør påbegyndes to dage før start af cytotoksisk behandling og fortsættes i mindst 7 dage. 
Febuxostat Krka should be started two days before the beginning of cytotoxic therapy and continued for a minimum of 7 days; however treatment may be prolonged up to 9 days according to chemotherapy duration as per clinical judgment.
De hyppigst rapporterede bivirkninger i kliniske forsøg (4.072 forsøgspersoner behandlet med doser fra mindst 10 mg til 300 mg) og efter markedsføring er udbrud af arthritis urica, leverpåvirkning, diarré, kvalme, hovedpine, udslæt og ødem. 
The most commonly reported adverse reactions in clinical trials (4,072 subjects treated at least with a dose from 10 mg to 300 mg) and post-marketing experience are gout flares, liver function abnormalities, diarrhoea, nausea, headache, rash and oedema.
Atrieflimren, palpitationer, unormalt EKG venstresidigt grenblok (se afsnittet Tumorlysesyndrom), sinustakykardi (se afsnittet Tumorlysesyndrom) 
Atrial fibrillation, palpitations, ECG abnormal, left bundle branch block (see section Tumor Lysis Syndrome), sinus tachycardia (see section Tumor Lysis Syndrome) Rare
Med hensyn til de sekundære endemål blev der ikke registreret nogen signifikant forskel i antal tilfælde af laboratorie-tumorlysesyndrom (8,1 % og 9,2 % i henholdsvis febuxostat- og allopurinol-armen, relativ risiko: 0,875 (95 % konfidensinterval: 0,4408; 1,7369); p=0,8488) og heller ikke i antal tilfælde af klinisk tumorlysesyndrom (1,7 % og 1,2 % i henholdsvis febuxostat- og allopurinol-armen; relativ risiko: 0,994 (95 % konfidensinterval: 0,9691; 1,0199); p=1,0000). 
With regard to secondary endpoints, no significant difference was detected in terms of incidence of laboratory TLS (8.1% and 9.2% in febuxostat and allopurinol arm, respectively; relative risk: 0.875 [95% confidence interval: 0.4408; 1.7369]; p=0.8488) nor of clinical TLS (1.7% and 1.2% in febuxostat and allopurinol arm, respectively; relative risk: 0.994 [95% confidence interval: 0.9691; 1.0199]; p=1.0000).
Andelen af forsøgspersoner, der krævede behandling for et udbrud af arthritis urica (APEX-studiet og FACT-studiet), var numerisk lavere i de grupper, der opnåede et gennemsnitligt serumuratniveau efter baseline på < 357 µmol/l (6,0 mg/dl), < 298 µmol/l (5,0 mg/dl) eller < 238 µmol/l (4,0 mg/dl) sammenlignet med den gruppe, der opnåede et gennemsnitligt serumuratniveau efter baseline på ≥ 6,0 mg/dl i løbet af de sidste 32 uger af behandlingsperioden (intervaller fra uge 20-24 til uge 49 
The proportion of subjects requiring treatment for a gout flare (APEX and FACT Study) was numerically lower in the groups that achieved an average post-baseline serum urate level <6.0 mg/dL, <5.0 mg/dL, or <4.0 mg/dL compared to the group that achieved an average post-baseline serum urate level ≥6.0 mg/dL during the last 32 weeks of the treatment period (Week 20-Week 24 to Week 49 - 52 intervals).
Primært endepunkt i undergruppen af patienter med nedsat nyrefunktion APEX-studiet evaluerede effekten hos 40 patienter med nedsat nyrefunktion (dvs. serumkreatinin > 90 µmol/l (1,5 mg/dl) og ≤ 119µmol/l (2,0 mg/dl) ved baseline). 
Primary endpoint in the sub-group of patients with renal impairment The APEX Study evaluated efficacy in 40 patients with renal impairment (i.e., baseline serum creatinine > 1.5 mg/dL and ≤2.0 mg/dL).
Andelen af patienter med serumuratniveauer på < 6,0 mg/dl (357 μmol/l) ved det sidste besøg var over 80 % (81-100%) for begge febuxostatdoser. 
The proportion of patients with serum urate levels of <6.0 mg/dL (357 μmol/L) at the final visit was greater than 80% (81-100%) at each febuxostat dose.
I et studie med raske forsøgsdeltagere havde samtidig administration af 120 mg febuxostat én gang dagligt og en enkelt oral dosis på 4 mg rosiglitazon ingen indvirkning på farmakokinetikken af rosiglitazon eller dets metabolit N-desmethyl rosiglitazon, hvilket tyder på, at febuxostat ikke hæmmer CYP2C8-enzymet in vivo. 
In a study in healthy subjects, coadministration of 120 mg febuxostat QD with a single 4 mg oral dose of rosiglitazone had no effect on the pharmacokinetics of rosiglitazone and its metabolite N-desmethyl rosiglitazone, indicating that febuxostat is not a CYP2C8 enzyme inhibitor in vivo.
Hvis du har glemt at tage Febuxostat Krka 
If you forget to take Febuxostat Krka